Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Day One Biopharmaceuticals

01/08/2025 22:13

Day One Biopharmaceuticals Inc DAWN.OQ DAWN.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The Brisbane California California-based  company is expected to report a 330.9% increase in revenue to $35.301 million from $8.19 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Day One Biopharmaceuticals Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 73.2% above its last closing price of $6.71

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.44
-0.44
-0.35
Beat
20.9
Dec. 31 2025
-0.36
-0.36
-0.64
Missed
-76.8
Sep. 30 2024
-0.42
-0.41
-0.37
Beat
9.8​
Jun. 30 2024
-0.77
-0.75
-0.05
Beat
93.3
​​Mar. 31 2024
-0.66
-0.66
-0.72
Missed
-8.5
Dec. 31 2023
-0.59
-0.58
-0.64
Missed
-9.7​
Sep. 30 2023
-0.59
-0.60
-0.54
Beat
10.3
Jun. 30 2023
-0.61
-0.61
-0.61
Met
0

This summary was machine generated August 1 at 21:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)